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The debate around relooking at stavudine dosing, both in terms of 
the adult low-dose stavudine study and more broadly, is welcome. 
The study being proposed to evaluate low-dose stavudine v. 
tenofovir is a fairly standard placebo-controlled non-inferiority 
study. The study design is not controversial; however, the choice 
of study drug has attracted critical attention. We have previously 
discussed the issue of stavudine use, cost and access, and the 
significant implications of stavudine in developing countries, in 
detail in a recent article.1 We continue to believe that low-dose 
stavudine clinical trials, in both adults and children, are a priority 
for developing countries. These studies are being proposed simply 
because tenofovir is very expensive, and the only available cheaper 
alternative is stavudine. With recession, unertainty about donor 
commitments, the compromise of several treatment projects by lack 
of money, and the plain fact that many developing countries are 
unable to take ownership of the antiretroviral programme within 
their budgets, this and similar studies are urgent and necessary for 
our region to continue to expand access to antiretroviral therapy.
Stavudine was chosen because it is very cheap, easily co-formulated, 
very well tolerated initially, and requires no laboratory toxicity 
monitoring in routine clinical practice. Tenofovir was chosen as 
the comparator for the trial as it is currently the ‘gold standard’ 
in many guidelines, and the alternatives (zidovudine (AZT) and 
abacavir) are now more expensive than tenofovir. Abacavir would 
be regarded as the equivalent gold standard for paediatric care.
As clinicians involved with antiretroviral (ARV) programmes for 
the last few years, and having used stavudine in large numbers of 
both adults and children in the past decade, we identify with the 
instinctive discomfort of many critics. However, we feel that there 
is a very strong case for studying stavudine further, and many of 
the arguments against further trials are not consistent with how 
we study other antiretrovirals, or indeed medication efficacy in 
general. Tenofovir certainly has benefits over stavudine: it is dosed 
daily, and has anti-hepatitis B activity; counter-arguments could 
be that hepatitis B is easily screened for, and that renal toxicity 
increasingly recognised with tenofovir has potentially serious 
consequences in developing countries, where monitoring and 
access to renal care, dialysis and transplantation are almost non-
existent.2 These arguments, however, are likely to be irrelevant 
when the cost of medication is considered. Broadly, other more 
substantial arguments fall into the following categories.
STAVUDINE TOXICIT Y
This is the most serious disagreement. Critics maintain that 
stavudine is too toxic to be used, that it is not possible to monitor 
toxicity safely, and that the trial duration is only 2 years, hence 
limiting the usefulness of the data.
Toxicity concerns are exclusively based on data around high dosages 
of stavudine, largely the (now historic) adult 40 mg twice a day 
(bd) dosage, for which there are extensive toxicity data, including 
from our own centres. More limited data suggest that 30 mg bd 
is significantly safer, at least in the medium term, but still carries 
significant toxicity. We do not contest this – stavudine causes often 
irreversible and stigmatising lipo-atrophy, as well as peripheral 
neuropathy and other mitochondrial toxicity in adults. However, 
all drugs are toxic in sufficient dosages. AZT was originally dosed 
at far higher levels than currently; toxicity forced the testing of 
lower doses that were far better tolerated with equal virological 
suppression levels, and AZT became the standard of first-line care 
for almost a decade. However, AZT still has some toxicity at this 
lower dose, and even lower doses are being tried.3-9
The original dose-finding studies of stavudine (d4T) were a 
complex affair, and the originator company did not complete what 
we consider to have been the natural next phase of study, largely 
as it was clear that the significant investment on another large 
clinical trial was unlikely to be recouped, as well as a probable 
internal assessment that the drug had a significant public relations 
problem related to lipo-atrophy in developed countries, where 
profits are made. There is some evidence that dosing at 20 mg bd is 
safer and gives equivalent virological efficacy, but these data have 
not been tested in a rigorous manner.5
This study plans to repeat those done for drugs such as AZT 
and many others – optimising the dosage of stavudine so as to 
minimise toxicity, while maintaining virological efficacy. It also 
responds to observer calls for more research on stavudine using 
high-quality trials.3,5,10
Critics have maintained that stavudine toxicity is impossible to 
monitor safely. Safety and toxicity monitoring in the proposed 
study has been extensively examined by many experts, and we are 
confident that we can pursue the study safely. Ethics committees are 
currently examining the proposed toxicity monitoring schedules. 
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The doctors involved in the study have plenty of experience in the 
early recognition of stavudine toxicity.
We agree with critics that the study will not give us evidence on 
long-term toxicity. Our study is currently funded to run for 2 years, 
like most registration ARV studies. For many countries, providing 2 
years of safe therapy at reduced cost is of significant importance. 
However, we have extensive lipo-atrophy pre-clinical toxicity 
monitoring built into the study; if no additional toxicity in the 
stavudine arm using DEXA scans is demonstrated, it is plausible 
that the drug could be used for longer, and we therefore intend 
motivating to extend the study.
Finally, it is contended that this study would never be run in a 
developed country. We see absolutely no scientific and ethical 
reasons why not. However, the urgency remains in our region. 
Rationing has already begun in many programmes, and universal 
access, with the attendant benefits of HIV prevention suggested 
by the HPTN 052 trial, is unlikely to be more than a public health 
dream unless we lower the cost of safe treatment. Even developed 
countries have had to make rationing decisions, cf. the recent 
decision to restrict access to first-line tenofovir in the UK; rationing 
was made easier by having good data to base these decisions on.
TENOFOVIR COST
It is asserted that the price of tenofovir is still dropping and will 
approach that of stavudine. We have consulted extensively over 
this with the Clinton Health Access Initiative (CHAI) as well as 
generic companies, and it seems that price equivalence will not be 
possible, simply because the daily milligram dosage (a daily 300 
mg v. the proposed 40 mg) is so different, as raw chemicals drive 
the generic manufacturing costs. Furthermore, the incremental 
drops in the price of tenofovir (the latest announced by the CHAI in 
January 2012) are unlikely to be as significant as previous ones, as 
manufacturing efficiencies have largely been realised.
NEW DRUG AVAILABILIT Y
The next assertion is that new drugs are in the offing and will be 
available by the time this study has results, making the results 
irrelevant. We believe that confidence in a new drug that will 
cost-effectively and timeously replace tenofovir is a huge act of 
faith. Many new medications are indeed being tested, and a small 
number may show efficacy when this study is completed. However, 
most drugs fail, even in phase 3 studies, so even this is uncertain. 
Also, the drugs may not be tested with backbones conventionally 
used in our context (e.g. raltegravir may be used instead of 
efavirenz), which may limit agreement on whether we can use the 
drug safely with available backbone drugs.
Furthermore, the registration process, local regulatory approval, 
negotiations with generic manufacturers and acceptance into 
national guidelines mean that it takes many years to go from 
clinical trial success to broad availability. Tenofovir took over 5 
years for registration in South Africa. Prolonged registration is the 
rule rather than the exception in many developing countries. We 
may need several more years for adequate costing, price reductions 
and agreement on priorities for access to this treatment. 
We believe that it is responsible to study alternatives to tenofovir 
and other expensive first-line medications.
OTHER ISSUES
In paediatric care, abacavir is the current preferred first-line 
drug owing to concerns about tenofovir toxicity and also to to 
preserve AZT for a second-line NRTI backbone. Abacavir is very 
expensive. Stavudine remains the most widely used ARV for HIV-
infected children in sub-Saharan Africa. Apart from cost, abacavir 
has other real problems. Although the incidence of abacavir 
hypersensitivity reactions is probably low, there is no confirmatory 
test widely available in the public sector. The HLA-B5701 gene test 
is simply not available outside large tertiary centres, and the gene 
appears to be a largely Caucasian one anyway. Nonspecific fever 
and rash are common in childhood, especially during immune 
reconstitution, and many children are likely to receive the label 
‘possible previous abacavir hypersensitivity reaction’, which 
eliminates the option of ever re-introducing abacavir in their 
regimen. Once abacavir is eliminated, the remaining options in 
sub-Saharan Africa are zidovudine  or  stavudine. The danger of 
zidovudine-related bone marrow suppression (a common problem 
with varying degrees of severity) is significant and requires some 
laboratory monitoring. Stavudine offers almost toxicity-free short-
term efficacy. For unknown reasons, thymidine-related peripheral 
neuropathy has not been documented in pre-pubertal children, 
and symptomatic lactic acidosis appears remarkably less common 
than in adults. The incidence of lipo-atrophy is concerning but is 
strongly dose-related. We think that its frequency and severity 
will be significantly reduced with the use of low-dose stavudine. 
In addition, stigmatising lipo-atrophy is avoidable if reasonable 
awareness is maintained and appropriate drug switches made 
before lipo-atrophy becomes obvious.9,11,12 An unrecognised 
benefit of using children’s regimens similar to adults’ is that it 
makes children less susceptible to supply-line problems, a huge 
problem in developing countries. Getting the dose of stavudine 
right in children is as compelling as it is in adults, and these studies 
should be prioritised by funders.
In the end, we desperately need alternatives to tenofovir for adults 
and to abacavir in children in poorer countries. The only current 
alternative is conventionally dosed stavudine, as AZT and abacavir 
are more expensive than tenofovir. A minister of health or donor 
faced with the decision to treat two people with a moderately toxic 
drug or one with a relatively safe regimen, with the other person 
definitely dying of AIDS, faces very little choice. Making stavudine 
safer is an urgent public health issue. We think that doing it safely, 
efficiently and ethically is possible and should be everyone’s priority.
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